Literature DB >> 12149218

Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells.

Elke Scandella1, Ying Men, Silke Gillessen, Reinhold Förster, Marcus Groettrup.   

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells that are able to initiate and modulate immune responses and are hence exploited as cellular vaccines for immunotherapy. Their capacity to migrate from peripheral tissues to the T-cell areas of draining lymph nodes is crucial for the priming of T lymphocytes. In this study, we investigated how the maturation of human monocyte-derived DCs (MoDCs) by several different stimuli under serum-free conditions affected their T-cell stimulatory function, cytokine secretion, and migratory behavior. Surprisingly, we found that for all maturation stimuli tested, the addition of prostaglandin E2 (PGE2) was required for effective migration of MoDCs toward the lymph node-derived chemokines CCL19 (EBI1 ligand chemokine/macrophage inflammatory protein--3beta) and CCL21 (secondary lymphoid tissue chemokine [SLC]/6Ckine). Costimulation with PGE2 enhanced the expression of the CCL19/CCL21 receptor CCR7 on the cell surface of MoDCs when they were matured with soluble CD40 ligand or proinflammatory cytokines, but did not affect CCR7 expression of polyI:C-stimulated MoDCs. The effects of PGE2 on MoDCs were mediated through increased cyclic adenosine monophosphate by 2 of the known PGE2 receptors, EP2 and EP4, which are expressed and down-regulated after PGE2 binding in these cells. In conclusion, our results suggest that signals provided by the proinflammatory mediator PGE2 are crucial for MoDCs to acquire potent T-helper cell stimulatory capacity and substantial chemotactic responsiveness to lymph node-derived chemokines. This is a new and important parameter for the preparation of MoDCs as cellular vaccines in tumor immunotherapy. (Blood. 2002;100:1354-1361)

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149218     DOI: 10.1182/blood-2001-11-0017

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  156 in total

1.  Distinctive role of efferocytosis in dendritic cell maturation and migration in sterile or infectious conditions.

Authors:  Letícia de Aquino Penteado; Naiara Naiana Dejani; Felipe Fortino Verdan; Allan Botinhon Orlando; Victoria Eugenia Niño; Fernanda De Nuzzi Dias; Ana Carolina Guerta Salina; Alexandra Ivo Medeiros
Journal:  Immunology       Date:  2017-04-10       Impact factor: 7.397

Review 2.  Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances.

Authors:  Gwendalyn J Randolph; Guzman Sanchez-Schmitz; Veronique Angeli
Journal:  Springer Semin Immunopathol       Date:  2005-01

3.  Slowing down with age: lung DCs do it too.

Authors:  Thomas J Braciale; Taeg S Kim
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

4.  Pore-formation by adenylate cyclase toxoid activates dendritic cells to prime CD8+ and CD4+ T cells.

Authors:  Martina Svedova; Jiri Masin; Radovan Fiser; Ondrej Cerny; Jakub Tomala; Marina Freudenberg; Ludmila Tuckova; Marek Kovar; Gilles Dadaglio; Irena Adkins; Peter Sebo
Journal:  Immunol Cell Biol       Date:  2015-10-06       Impact factor: 5.126

Review 5.  Human dendritic cell subsets for vaccination.

Authors:  Peter Dubsky; Hideki Ueno; Bernard Piqueras; John Connolly; Jacques Banchereau; A Karolina Palucka
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

Review 6.  Mast cells as regulators of adaptive immunity to tumours.

Authors:  A Wasiuk; V C de Vries; K Hartmann; A Roers; R J Noelle
Journal:  Clin Exp Immunol       Date:  2008-12-05       Impact factor: 4.330

Review 7.  DC-based cancer vaccines.

Authors:  Eli Gilboa
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Secretory phospholipase A2 induces dendritic cell maturation.

Authors:  Laure Perrin-Cocon; Sophie Agaugué; Frédéric Coutant; Aurélie Masurel; Sofiane Bezzine; Gérard Lambeau; Patrice André; Vincent Lotteau
Journal:  Eur J Immunol       Date:  2004-08       Impact factor: 5.532

Review 9.  Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4.

Authors:  Pawel Kalinski
Journal:  Curr Opin Investig Drugs       Date:  2009-06

10.  Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking.

Authors:  Brooke M Helfer; Anthony Balducci; Aaron D Nelson; Jelena M Janjic; Roberto R Gil; Pawel Kalinski; I Jolanda M de Vries; Eric T Ahrens; Robbie B Mailliard
Journal:  Cytotherapy       Date:  2010-04       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.